CytomX Therapeutics (CTMX)

• Market cap: $58.5M
• 1 day: 14.23%
• 5 days: 4.35%
• 1 month: 17.07%
• 3 months: -14.94%
• 6 months: -24.97%
• Year to date: -29.78%
• 1 year: -54.34%
• 5 years: -92.79%
• 10 years: -94.23%
• Sector: Healthcare
• Industry: Biotechnology

About: CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Employees: 121

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

620% more call options, than puts

Call options by funds: $36K | Put options by funds: $5K

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

14% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 21

1% more funds holding

Funds holding: 69 [Q3] → 70 (+1) [Q4]

5.84% less ownership

Funds ownership: 65.53% [Q3] → 59.69% (-5.84%) [Q4]

20% less capital invested

Capital invested by funds: $60.4M [Q3] → $48.1M (-$12.3M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $2.50 236% upside
• Avg. target: $2.50 236% upside
• High target: $2.50 236% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Joseph Catanzaro 50% 1-year accuracy 12 / 24 met price target

236% upside $2.50

Overweight Maintained

14 Apr 2025